Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Syndax Pharmaceuticals (SNDX) Net Income towards Common Stockholders (2016 - 2020)

Syndax Pharmaceuticals (SNDX) has 6 years of Net Income towards Common Stockholders data on record, last reported at -$19.9 million in Q4 2020.

  • For Q4 2020, Net Income towards Common Stockholders fell 39.81% year-over-year to -$19.9 million; the TTM value through Sep 2021 reached -$19.9 million, up 69.8%, while the annual FY2025 figure was -$285.4 million, 10.46% up from the prior year.
  • Net Income towards Common Stockholders reached -$19.9 million in Q4 2020 per SNDX's latest filing, roughly flat from -$19.9 million in the prior quarter.
  • Across five years, Net Income towards Common Stockholders topped out at -$8.4 million in Q2 2016 and bottomed at -$19.9 million in Q4 2020.
  • Average Net Income towards Common Stockholders over 5 years is -$15.4 million, with a median of -$15.1 million recorded in 2017.
  • Peak YoY movement for Net Income towards Common Stockholders: crashed 145.93% in 2016, then rose 26.52% in 2019.
  • A 5-year view of Net Income towards Common Stockholders shows it stood at -$10.9 million in 2016, then tumbled by 74.99% to -$19.0 million in 2017, then fell by 1.61% to -$19.3 million in 2018, then grew by 26.52% to -$14.2 million in 2019, then tumbled by 39.81% to -$19.9 million in 2020.
  • Per Business Quant database, its latest 3 readings for Net Income towards Common Stockholders were -$19.9 million in Q4 2020, -$19.9 million in Q3 2020, and -$16.6 million in Q2 2020.